Parkinson Disease in a Patient with Multiple Co-morbidities: A Delayed Diagnosis? by King, Theresa L.
KANSAS JOURNAL of  M E D I C I N E
60
Parkinson Disease in a Patient with Multiple 
Co-morbidities: A Delayed Diagnosis?
Theresa L. King, M.D. 
University of Kansas Medical Center, Kansas City, KS
Department of Internal Medicine, Division of General and 
Geriatric Medicine
INTRODUCTION
 Parkinson disease (PD) is a progressive neurodegenera-
tive disorder with an estimated prevalence of 0.3% in the Unit-
ed States, while in those individuals 85 years and older, the 
prevalence increases to 4 - 5%.1 It is a condition that can be dif-
ficult to identify, especially in patients with multiple comor-
bidities, where signs and symptoms may overlap significantly. 
CASE REPORT
 A 64-year-old male with previous diagnoses of chronic in-
flammatory demyelinating polyneuropathy (CIDP), ulcer-
ative colitis resulting in a remote partial small bowel resec-
tion, rheumatoid arthritis, and monoclonal gammopathy of 
unknown significance presented to the hospital with com-
plaints of intractable abdominal pain, primarily post-prandial, 
and significant weight loss. His body mass index was 16 and 
vital signs were within normal limits. Review of symptoms 
revealed difficulty walking, frequent falls, tremor, and prob-
lems with memory. His physical exam revealed an abdomen 
mildly tender to deep palpation. He exhibited a stooped, lor-
dotic posture and an unsteady, relatively wide-based gait. 
Routine labs indicated a stable anemia with hemoglobin of 11.9 
g/dl. Esophagogastroduodenoscopy, colonoscopy, and gastric 
emptying study were unremarkable. An abdominal computer 
tomography (CT) scan showed possible bowel ischemia and 
vascular surgery was consulted. An abdominal CT angiogram 
(CTA) showed marked focal stenosis of the celiac artery ori-
gin, inferior mesenteric artery origin, and proximal to mid su-
perior mesenteric artery. He was taken to the operating room 
for angioplasty and stent placement of affected vessels. His 
abdominal pain improved and his caloric intake increased suf-
ficiently for discharge. At follow-up with neurology, the possi-
bility of Parkinson disease (PD) was raised and he underwent 
a DaTScan, which uses single photon emission computed to-
mography (SPECT) brain imaging to assist in the evaluation of 
patients with suspected Parkinsonian syndromes. The DaTScan 
showed no activity in the bilateral putamen and only faint ac-
tivity in the bilateral caudate nuclei, with slightly more activ-
ity seen on the left. These findings were consistent with PD.
The patient recalled that symptoms initially began in 2006 
with tremors in his right hand. It was thought to be an essen-
tial tremor, as several individuals in his family had the same. 
Although he had several features not typical of PD, including 
having a long history of tremors, severe CIDP, and the lack of 
a typical resting tremor, he was started on carbidopa/levodopa 
and his tremors and gait improved. While diagnosis and treat-
ment of PD did not resolve every symptom, it improved the pa-
tient’s function and safety, making this an important finding.
DISCUSSION 
 Parkinson disease is a progressive degeneration of the central 
nervous system, mainly affecting the motor system.2 Charac-
teristic neuropathologic features of the disease are dopaminer-
gic neuron degeneration in the substantia nigra and the pres-
ence of eosinophilic intracytoplasmic inclusions (Lewy bodies) 
in the residual dopaminergic neurons. The etiology is likely 
multifactorial, with hereditary predisposition, environmen-
tal factors, and physiologic changes of aging all contributing. 
The disease encompasses a range of severity, from “parkin-
sonism”, manifested by minimal, non-life-altering symptoms, 
to full-blown disease that greatly affects activities of daily liv-
ing. PD generally presents with gait instability, changes in 
memory and cognition, slowed movement (bradykinesia), 
postural instability often resulting in falls, increased muscle 
rigidity or the development of masked facies. Lesser mani-
festations of these signs and symptoms can be subtle and dif-
ficult to recognize. Onset is often unilateral and may include 
other abnormal movements, such as postural or action tremors.
 Patients may complain of insomnia, depression, anxiety, fa-
tigue, constipation, dysautonomia, and anosmia.2 Later in the 
disease, psychosis, involving visual hallucinations and delu-
sions, and dementia occur in up to 25% of patients. A differen-
tial diagnosis must include Lewy body dementia, progressive 
supranuclear palsy (PSP), corticobasal degeneration (CBD), 
essential tremor, post-encephalitic conditions, and Alzheim-
er disease, as all can mimic PD.2 Parkinson disease is the sec-
ond most common neurodegenerative disorder, following 
Alzheimer disease, and is more common among Hispanics 
and non-Hispanic whites than Asians and African Americans.
 The American Academy of Neurology (AAN) recom-
mends initial treatment with levodopa or a dopamine 
agonist, depending on whether the need is to improve 
motor disability (levodopa is better) or decrease motor com-
plications (dopamine agonists cause fewer motor compli-
cations), replacing endogenous dopamine in the form of 
levodopa, which is converted to dopamine in the brain.3  Le-
vodopa is effective at controlling bradykinesia and rigidity.
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Levodopa is combined with carbidopa, which prevents periph-
eral conversion to dopamine by blocking dopa decarboxylase. 
Other effective agents which directly stimulate dopamine re-
ceptors include bromocriptine (Parlodel), pergolide (Permax), 
pramipexole (Mirapex), and ropinirole (Requip). Inhibitors 
of catechol-O-methyltransferase (COMT), including entaca-
pone (Comtan) and tolcapone (Tasmar), decrease the break-
down of levodopa and extend its half-life, lessening the end-
of-dose wearing-off effect. Amantadine, an antiviral, provides 
benefits lasting for less than eight months, with its withdraw-
al resulting in a 10% to 20% rebound increase in dyskinesia.4 
Anticholinergics can be used to treat the depression, demen-
tia, and psychoses that develop in 20% to 40% of patients.5 
 The Unified Parkinson Disease Rating Scale (UPDRS; avail-
able at http://www.mdvu.org/pdf/updrs.pdf) is a standard 
assessment tool that provides a measure of disease progres-
sion and treatment response.6 The four-part scale measures 
mental effects, limitations in activities of daily living (ADLs), 
motor impairment, and treatment or disease complications. 
 Treatment of advanced or disabling symptoms can include 
deep brain stimulation of the subthalamic nucleus or globus pal-
lidus.2 Deep brain stimulation of the subthalamic nucleus effec-
tively improves motor function and reduces motor fluctuations, 
dyskinesia, and antiparkinsonian medication use.7 Parkinson-
ism-directed physical therapy is often effective in reducing falls.
CONCLUSION
 This case report illuminates that diagnoses often are de-
layed, especially when signs and symptoms overlap with 
other diseases. In a patient with multiple medical comorbidi-
ties, it can be challenging to diagnose this insidious disease.
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